Research based on this theory has investigated physiological mechanisms at every level of the pathway, from receptors to cerebral cortex, and has produced a variety of drugs to control acute pain ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Acute pain is short-term pain often caused by surgery ... According to the FDA, Journavx “reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous ...

This new drug is a non-opioid analgesic, the first of its kind, designed to treat moderate to severe acute pain in adults. Journavx works by targeting a pain-signaling pathway involving sodium ...

There is good news for those with acute pain, as the FDA has approved a first-of-its-kind pain medication, and it’s one ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx as the first novel mechanism for acute pain in decades.